PURPOSE: LY3022859 is an anti-TGFβRII IgG1 monoclonal antibody that inhibits receptor-mediated signaling activation. The primary objective of this phase I study was to determine a phase II dose in patients with advanced solid tumors. Secondary objectives were to assess safety and pharmacokinetics (PK). METHODS: LY3022859 was infused intravenously (IV) at 1.25 mg/kg over 1 h every 2 weeks (Q2W) (cohort 1A) and at flat doses of 12.5 mg (cohort 1B) and 25 mg (cohort 2) over 3 h Q2W. RESULTS: Fourteen patients were enrolled in cohorts 1A (n = 2), 1B (n = 5), and 2 (n = 7). DLTs were experienced by both patients in cohort 1A (infusion-related reaction) and 2 patients in cohort 2 (cytokine release syndrome and infusion-related reaction). No MTD was determined. At the 25 mg dose level (cohort 2), after fifth infusion, LY3022859 had a short t1/2 (4.37-7.80 h) and rapid clearance (CLss, 0.412 L/h). Exposure increased twofold (from 28.5 to 60.2 μg·h/mL) with increase in dose from 12.5 to 25 mg. No accumulation was observed after repeat administration. CONCLUSIONS: The MTD for LY3022859 was not determined. Dose escalation beyond 25 mg was considered unsafe due to worsening symptoms (uncontrolled cytokine release) despite prophylaxis (corticosteroids and antihistamines). TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01646203.
PURPOSE:LY3022859 is an anti-TGFβRII IgG1 monoclonal antibody that inhibits receptor-mediated signaling activation. The primary objective of this phase I study was to determine a phase II dose in patients with advanced solid tumors. Secondary objectives were to assess safety and pharmacokinetics (PK). METHODS:LY3022859 was infused intravenously (IV) at 1.25 mg/kg over 1 h every 2 weeks (Q2W) (cohort 1A) and at flat doses of 12.5 mg (cohort 1B) and 25 mg (cohort 2) over 3 h Q2W. RESULTS: Fourteen patients were enrolled in cohorts 1A (n = 2), 1B (n = 5), and 2 (n = 7). DLTs were experienced by both patients in cohort 1A (infusion-related reaction) and 2 patients in cohort 2 (cytokine release syndrome and infusion-related reaction). No MTD was determined. At the 25 mg dose level (cohort 2), after fifth infusion, LY3022859 had a short t1/2 (4.37-7.80 h) and rapid clearance (CLss, 0.412 L/h). Exposure increased twofold (from 28.5 to 60.2 μg·h/mL) with increase in dose from 12.5 to 25 mg. No accumulation was observed after repeat administration. CONCLUSIONS: The MTD for LY3022859 was not determined. Dose escalation beyond 25 mg was considered unsafe due to worsening symptoms (uncontrolled cytokine release) despite prophylaxis (corticosteroids and antihistamines). TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01646203.
Authors: Christopher P Denton; Peter A Merkel; Daniel E Furst; Dinesh Khanna; Paul Emery; Vivien M Hsu; Nancy Silliman; James Streisand; John Powell; Anita Akesson; John Coppock; Frank van den Hoogen; Ariane Herrick; Maureen D Mayes; Douglas Veale; Joanna Haas; Stephen Ledbetter; Joseph H Korn; Carol M Black; James R Seibold Journal: Arthritis Rheum Date: 2007-01
Authors: U Bogdahn; P Hau; G Stockhammer; N K Venkataramana; A K Mahapatra; A Suri; A Balasubramaniam; S Nair; V Oliushine; V Parfenov; I Poverennova; M Zaaroor; P Jachimczak; S Ludwig; S Schmaus; H Heinrichs; K-H Schlingensiepen Journal: Neuro Oncol Date: 2010-10-27 Impact factor: 12.300
Authors: Howard Trachtman; Fernando C Fervenza; Debbie S Gipson; Peter Heering; David R W Jayne; Harm Peters; Stefano Rota; Giuseppe Remuzzi; L Christian Rump; Lorenz K Sellin; Jeremy P W Heaton; James B Streisand; Marjie L Hard; Steven R Ledbetter; Flavio Vincenti Journal: Kidney Int Date: 2011-03-02 Impact factor: 10.612
Authors: Julius Strauss; Christopher R Heery; Jeffrey Schlom; Ravi A Madan; Liang Cao; Zhigang Kang; Elizabeth Lamping; Jennifer L Marté; Renee N Donahue; Italia Grenga; Lisa Cordes; Olaf Christensen; Lisa Mahnke; Christoph Helwig; James L Gulley Journal: Clin Cancer Res Date: 2018-01-03 Impact factor: 12.531
Authors: Kojo Agyemang; Allan M Johansen; Grayson W Barker; Michael J Pennison; Kimberly Sheffield; Hugo Jimenez; Carl Blackman; Sambad Sharma; Patrick A Fordjour; Ravi Singh; Katherine L Cook; Hui-Kuan Lin; Wei Zhang; Hui-Wen Lo; Kounosuke Watabe; Peiqing Sun; Carl D Langefeld; Boris Pasche Journal: NPJ Breast Cancer Date: 2022-07-19
Authors: Melody G Campbell; Anthony Cormier; Saburo Ito; Robert I Seed; Andrew J Bondesson; Jianlong Lou; James D Marks; Jody L Baron; Yifan Cheng; Stephen L Nishimura Journal: Cell Date: 2020-01-16 Impact factor: 41.582
Authors: Robert I Seed; Kenji Kobayashi; Saburo Ito; Naoki Takasaka; Anthony Cormier; Jillian M Jespersen; Jean Publicover; Suprita Trilok; Alexis J Combes; Nayvin W Chew; Jocelyne Chapman; Matthew F Krummel; Jianlong Lou; James Marks; Yifan Cheng; Jody L Baron; Stephen L Nishimura Journal: Sci Immunol Date: 2021-03-26
Authors: Brian T Welsh; Ryan Faucette; Sanela Bilic; Constance J Martin; Thomas Schürpf; David Chen; Samantha Nicholls; Janice Lansita; Ashish Kalra Journal: Int J Toxicol Date: 2021-03-19 Impact factor: 2.032